• Dehydroepiandrosterone in PCOS Research

  2026-10-06

  A source-grounded overview of Dehydroepiandrosterone (DHEA) in polycystic ovary syndrome research, comparing human, animal and cell-based evidence while distinguishing model effects from therapeutic claims.

• p53 mRNA Delivery: Mechanism to Translation

  2026-10-05

  A source-grounded perspective on how transient p53 mRNA research can connect tumor-suppressor biology, lipid nanoparticle delivery, validation strategy, and translational decision-making without overstating preclinical or clinical evidence.

• Staurosporine: Research Context and Evidence

  2026-10-05

  A source-grounded overview of Staurosporine as a broad-spectrum serine/threonine protein kinase inhibitor, emphasizing conceptual research applications, published findings, evidence quality, mechanistic interpretation, and translational limitations.

• JHU-083 in Glutaminase and Neuroinflammation Research

  2026-10-04

  JHU-083 is described by APExBIO as a 6-diazo-5-oxo-L-norleucine precursor for studying glutaminase-linked metabolism, particularly in experimental cerebral malaria and related neurological disease models. The available material supports a cautious distinction between supplier-described applications and published evidence: the supplied 2026 study provides important redox biology in α-amanitin hepatotoxicity, but it did not test JHU-083 and cannot establish efficacy, selectivity, or translational value for this compound.

• Vernakalant Injection for Rapid AF Conversion

  2026-10-03

  The ACT-III trial evaluated RSD1235, or Vernakalant Hydrochloride injection, as a rapid pharmacological approach to converting atrial fibrillation to sinus rhythm. Its randomized evidence showed substantially greater short-duration AF conversion than placebo, while also identifying important limits related to patient selection, atrial flutter, and cardiovascular safety.

• Dehydroepiandrosterone (DHEA) Research Workflows

  2026-10-02

  Dehydroepiandrosterone (DHEA) supports distinct workflows for modeling ovarian endocrine stress, granulosa cell proliferation, and neural survival. This guide translates the latest DHEA-induced PCOS findings into formulation, assay-design, and troubleshooting decisions while preserving a separate route for neuroprotection studies.

• Cisplatin Workflow for Resistance Research

  2026-10-01

  Build more informative Cisplatin experiments by pairing viability measurements with apoptosis, oxidative-stress, and ferroptosis readouts. This workflow translates a recent resistance study into practical assay design for cancer research, including cautious extensions toward xenograft validation.

• Sumatriptan Succinate: Research Workflows

  2026-10-01

  Build reproducible receptor, inflammation, metabolism, and translational migraine assays around Sumatriptan Succinate. A pediatric emergency pathway shows how intranasal delivery can be evaluated as a practical first-line strategy while bench workflows clarify receptor selectivity and mechanism.

• Tropisetron Hydrochloride: Assay Workflows

  2026-09-30

  Tropisetron Hydrochloride supports more than a conventional receptor-blocking experiment: it can connect 5-HT3 signaling, α7-nicotinic receptor biology, and renal organic-cation transport in one research strategy. This guide translates its pharmacology into practical cell-based workflows, controls, troubleshooting steps, and assay-design decisions.

• GSTA1, Glutathione, and α-Amanitin Toxicity

  2026-09-30

  The reference study identifies GSTA1 as an unexpected driver of α-amanitin hepatotoxicity rather than a purely protective detoxification enzyme. By combining mouse injury models, multi-omics, binding assays, and genetic perturbation, it links GSTA1 upregulation to glutathione depletion, reactive oxygen species accumulation, and hepatocyte injury.

• Brefeldin A in Endothelial Trafficking Research

  2026-09-29

  Brefeldin A is more than a vesicle transport inhibitor: it can help dissect how secretory trafficking intersects with endothelial barrier assays. This article uses sepsis biomarker research to define a careful, hypothesis-driven framework for applying BFA without confusing trafficking effects with direct moesin signaling.

• JHU-083: Designing Better Glutaminase Assays

  2026-09-29

  JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor for selective glutaminase pathway studies in cerebral CD11b cells. This article translates a new GSTA1 hepatotoxicity study into a rigorous framework for interpreting glutamate, redox, and target-engagement data without overextending cross-disease evidence.

• Haloprogin: Applied Antifungal Workflows

  2026-09-28

  Haloprogin supports a practical bridge from low-dose dermatophyte screening to topical infection-model design, with activity spanning fungi, yeasts, and selected Gram-positive bacteria. This guide turns historical assay parameters into reproducible workflows, formulation choices, and troubleshooting decisions for modern bench research.

• Gamithromycin: Reading PK/PD Beyond the MIC

  2026-09-28

  Gamithromycin (ML-1709460) illustrates why an antibiotic MIC is only part of the susceptibility story. This article unpacks serum effects, exposure–response targets, and distinct cutoff values to help researchers design and interpret piglet assays without mistaking modeled results for universal dosing guidance.

• EdU Imaging Kits (488): Reading S-Phase in HCC

  2026-09-27

  EdU Imaging Kits (488) reveal DNA synthesis in S phase, but a meaningful proliferation result depends on how the signal is interpreted. Using HAUS1 research in hepatocellular carcinoma as a case study, this article shows how EdU can strengthen functional experiments without being mistaken for a standalone measure of tumor growth or immune biology.

8600 records 5/574 page Previous Next 12345 下5页 Last page